RECORDED: November 15, 2022, 9:00 am – 10:00 am EST Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls As regulatory approvals for long-acting, injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) against HIV move forward,...
Abstract: Introduction: Male clients (MCs) are integral to sex work-driven HIV transmission dynamics as sexual partners of female sex worker (FSW). MCs contribute disproportionately to incident HIV globally and in sub-Saharan Africa, with 27% of new infections...
Article and Study Summary: Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Published in: N Engl J Med. 2022;387(9):810-823 Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Authors: Conradie F, Bagdasaryan TR, Borisov...
Abstract: In 2021, long-acting cabotegravir (LA CAB) was approved by the United States Food and Drug Administration for an indication of pre-exposure prophylaxis in women. This is a first in what is hoped to be a robust pipeline of long-acting antiretroviral agents...
Article and Study Summary: Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial Published in: Lancet HIV. 2022;9(7):e464-e473 https://doi.org/10.1016/S2352-3018(22)00126-6 Authors: Ngure...
